[ASCO]
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
文献作者：Sibylle Loibl; Jacek Jassem; Amir Sonnenblick; Damien Parlier; Eric Winer; Jonas Bergh; Richard D. Gelber; Eleonora Restuccia; Young-Hyuck Im; Chiun-Sheng Huang; Florence Dalenc; Isabel Calvo; Marion Procter; Carmela Caballero; Emma Clark; Alice Raimbault; Robin McConnell; Estefania Monturus; Evandro de Azambuja; Henry L. Gomez; Judith Bliss; Giuseppe Viale; Jose Bines; Martine Piccart; ; Stefan Aebi; Michael Andersson; Jonas Bergh; José Bines; Judith Bliss; Hervé Bonnefoi; Carmela Caballero; David Cameron; Fatima Cardoso; Emma Clark; Evandro de Azambuja; Sanne de Haas; Susan Dent; Luis Fein; Elizabeth Frank; Richard Gelber; Michael Gnant; Henry Gomez Moreno; Seock-Ah Im; Christian Jackisch; Wolfgang Janni; Jacek Jassem; Ian Krop; Sherko Kümmel; Tsang-Wu Liu; Sherene Loi; Sibylle Loibl; Norikazu Masuda; Einav Nili Gam-Yal; Beatrice Nyawira; Tomas Pascual; Martine Piccart; Tadeusz Pienkowski; Marion Procter; Eleonora Restuccia; Alvaro Rodríguez-Lescure; Thomas Suter; Christoph Thomssen; Vivianne Tjan-Heijnen; Gianluca Tomasello; Manuel Roberto Torres Ulloa; Chris Twelves; Giuseppe Viale; Janice Walshe; Nicholas Wilcken; Eric Winer
